{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408610027
| IUPAC_name = (±)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
| image = Mirtazapine 2D structure.svg
| width = 150px
| image2 = Mirtazapine-3D-ball-model.png
| width2 = 175px
| imagename = 1 : 1 mixture (racemate)
| drug_name = 米氮平

<!--Clinical data-->
| tradename = 瑞美隆（中国大陆）/樂活憂（港台）（Remeron）
| Drugs.com = {{drugs.com|monograph|mirtazapine}}
| MedlinePlus = a697009
| licence_US = Mirtazapine
| pregnancy_US = C
| pregnancy_AU = B3
| legal_AU = S4
| legal_CA = Rx-only
| legal_US = Rx-only
| legal_UK = POM
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 50%<ref name="pmid10885584">{{cite journal | author = Timmer, CJ; Sitsen, JM; Delbressine, LP | title = Clinical pharmacokinetics of mirtazapine | journal = Clinical Pharmacokinetics | volume = 38 | issue = 6 | pages = 461–74 | date = June 2000 | pmid = 10885584 | doi = 10.2165/00003088-200038060-00001 | url = http://content.wkhealth.com/linkback/openurl?issn=0312-5963&volume=38&issue=6&spage=461 }}{{dead link|date=2018年4月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name = DM/><ref name = AXIT/><ref name = EMC/>
| protein_bound = 85%<ref name="pmid10885584" /><ref name = DM/><ref name = AXIT>{{cite web|title=Axit Mirtazapine PRODUCT INFORMATION|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05345-3|work=TGA eBusiness Services|publisher=alphapharm|accessdate=15 October 2013|date=25 October 2011}}</ref><ref name=EMC>{{cite web|title=Mirtazapine 30 mg Tablets - Summary of Product Characteristics|date=20 March 2013|accessdate=24 October 2013|format=PDF|url=http://www.medicines.org.uk/emc/medicine/25201/SPC/Mirtazapine+30+mg+Tablets/|work=electronic Medicines Compendium|publisher=Sandoz Limited|archive-url=https://web.archive.org/web/20131029192723/http://www.medicines.org.uk/emc/medicine/25201/SPC/Mirtazapine+30+mg+Tablets/|archive-date=2013-10-29|dead-url=yes}}</ref>
| metabolism = [[肝脏|肝脏]] ([[CYP1A2|CYP1A2]], [[CYP2D6|CYP2D6]] 和 [[CYP3A4|CYP3A4]])<ref name="pmid10885584" /><ref name = DM/><ref name = AXIT/><ref name = EMC/><ref name="pmid11607047">{{cite journal | author = Anttila, SA; Leinonen, EV | title = A review of the pharmacological and clinical profile of mirtazapine | journal = CNS Drug Reviews | volume = 7 | issue = 3 | pages = 249–64 | year = 2001 | pmid = 11607047 | doi = 10.1111/j.1527-3458.2001.tb00198.x| url = }}</ref>
| elimination_half-life = 20–40小时<ref name="pmid10885584" /><ref name = DM/><ref name = AXIT/><ref name = EMC/>
| excretion = 尿液 (75%)<ref name="pmid10885584" /><br />粪便 (15%)<ref name="pmid10885584" /><ref name = DM/><ref name = AXIT/><ref name = EMC/>

<!--Identifiers-->
| IUPHAR_ligand = 7241
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 61337-67-5
| ATC_prefix = N06
| ATC_suffix = AX11
| PubChem = 4205
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00370
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4060
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = A051Q2099Q
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00563
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 6950
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 654

<!--Chemical data-->
| C = 17 | H = 19 | N = 3
| molecular_weight = 265.35 g/mol
| smiles = n1cccc3c1N4C(c2ccccc2C3)CN(C)CC4
| InChI = 1/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
| InChIKey = RONZAEMNMFQXRA-UHFFFAOYAY
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RONZAEMNMFQXRA-UHFFFAOYSA-N
| synonyms = 6-Azamianserin, Org 3770
| density = 1.22
| melting_point = 114
| melting_high = 116
| boiling_point = 432
| solubility = 溶于[[甲醇|甲醇]]和[[氯仿|氯仿]]
}}

'''米氮平（{{lang-en|Mirtazapine}}）'''，商品名为'''樂活憂（港台）/瑞美隆（中国大陆）（Remeron）'''<ref name = MD>{{cite book|editor=Brayfield, A|title=Mirtazapine|work=Martindale: The Complete Drug Reference|publisher=The Royal Pharmaceutical Society of Great Britain|accessdate=3 November 2013|date=30 January 2013|url=http://www.medicinescomplete.com/mc/martindale/current/11022-r.htm|archive-date=2020-03-12|archive-url=https://web.archive.org/web/20200312210050/https://about.medicinescomplete.com/|dead-url=yes}}</ref>，是一种[[去甲肾上腺素和特异性5-羟色胺能抗抑郁药|去甲肾上腺素和特异性5-羟色胺能抗抑郁药]] ([[去甲肾上腺素和特异性5-羟色胺能抗抑郁药|NaSSA]]) <ref name = DM>{{cite web | title = REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=010f9162-9f7f-4b6d-a6e4-4f832f26f38e | work = DailyMed | publisher = Organon Pharmaceuticals USA | date = October 2012 | accessdate=24 October 2013}}</ref> ，主要用来治疗[[抑郁症|抑郁症]]。米氮平也经常被用作[[抗焦虑药|抗焦虑药]]、[[安眠药|安眠药]]、[[止吐药|止吐药]]和[[食欲促进剂|食欲促进剂]]。若按[[分子结构|分子结构]]分类，米氮平被分类为[[四环类抗抑郁药|四环类抗抑郁药]](TeCA) ，并且为[[米安舍林|米安舍林]]的6-[[氮杂|氮杂]]类似物。<ref name = MD/> 米氮平也是一种[[外消旋混合物|外消旋混合物]]，包含(''R'')- 和 (''S'')-[[异构体|异构体]]。<ref name = MD/>

==医疗用途==

===已批准的和适应症外使用===
米氮平主要用来治疗[[重度抑郁症|重度抑郁症]]和其他精神障碍。<ref name="pmid10446735">{{cite journal | author = Gorman, JM | title = Mirtazapine: clinical overview | journal = J Clin Psychiatry | volume = 60 Suppl 17 | issue = | pages = 9–13; discussion 46–8 | year = 1999 | pmid = 10446735 | doi = }}</ref><ref name="pmid21644844">{{cite journal | author = Benjamin, S; Doraiswamy, PM | title = Review of the use of mirtazapine in the treatment of depression | journal = Expert Opinion on Pharmacotherapy | volume = 12 | issue = 10 | pages = 1623–32 |date=July 2011 | pmid = 21644844 | doi = 10.1517/14656566.2011.585459 | url = http://informahealthcare.com/doi/abs/10.1517/14656566.2011.585459}}</ref>

然而研究发现，米氮平对以下症状也有一定疗效，所以米氮平有时候也会被以[[适应症外使用|适应症外使用]]的形式处方给以下症状的治疗：
{{colbegin|2}}
* [[广泛性焦虑症|广泛性焦虑症]]<ref name="pmid11607047" /><ref name="pmid10453798">{{cite journal | author = Goodnick, PJ; Puig, A; DeVane, CL; Freund, BV | title = Mirtazapine in major depression with comorbid generalized anxiety disorder | journal = J Clin Psychiatry | volume = 60 | issue = 7 | pages = 446–8 |date=July 1999 | pmid = 10453798 | doi = 10.4088/JCP.v60n0705 }}</ref>
* [[社交恐惧症|社交恐惧症]]<ref name="pmid19453203">{{cite journal | author = Croom, KF; Perry, CM; Plosker, GL | title = Mirtazapine: a review of its use in major depression and other psychiatric disorders | journal = CNS Drugs | volume = 23 | issue = 5 | pages = 427–52 | year = 2009 | pmid = 19453203 | doi = 10.2165/00023210-200923050-00006 | url = http://content.wkhealth.com/linkback/openurl?issn=1172-7047&volume=23&issue=5&spage=427 | access-date = 2015-08-31 | archive-date = 2013-02-09 | archive-url = https://archive.is/20130209231032/http://content.wkhealth.com/linkback/openurl?issn=1172-7047&volume=23&issue=5&spage=427 | dead-url = yes }}</ref><ref name="pmid16282842">{{cite journal | author = Muehlbacher, M; Nickel, MK; Nickel, C; et al. | title = Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study | journal = Journal of Clinical Psychopharmacology | volume = 25 | issue = 6 | pages = 580–3 |date=December 2005 | pmid = 16282842 | doi = 10.1097/01.jcp.0000186871.04984.8d| url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=25&issue=6&spage=580}}</ref>
* [[强迫症|强迫症]]<ref name="pmid19453203" /><ref name="pmid11593084">{{cite journal | author = Koran, LM; Quirk, T; Lorberbaum, JP; Elliott, M | title = Mirtazapine treatment of obsessive-compulsive disorder | journal = J Clin Psychopharmacol | volume = 21 | issue = 5 | pages = 537–9 |date=October 2001 | pmid = 11593084 | doi = 10.1097/00004714-200110000-00016 }}{{Unreliable medical source|date=October 2011}}</ref>
* [[恐慌症|恐慌症]]<ref name="pmid19453203" /><ref name="pmid10440525">{{cite journal | author = Carpenter, LL; Leon, Z; Yasmin, S; Price, LH | title = Clinical experience with mirtazapine in the treatment of panic disorder | journal = Ann Clin Psychiatry | volume = 11 | issue = 2 | pages = 81–6 |date=June 1999 | pmid = 10440525 | doi = 10.3109/10401239909147053 }}{{Unreliable medical source|date=October 2011}}</ref><ref name="pmid12090820">{{cite journal | author = Carli, V; Sarchiapone, M; Camardese, G; Romano, L; DeRisio, S | title = Mirtazapine in the treatment of panic disorder | journal = Arch. Gen. Psychiatry | volume = 59 | issue = 7 | pages = 661–2 |date=July 2002 | pmid = 12090820 | doi = 10.1001/archpsyc.59.7.661 }}{{Unreliable medical source|date=October 2011}}</ref>
* [[创伤后应激障碍|创伤后应激障碍]]<ref name="pmid19453203" />
* [[食欲不振|食欲不振]]/[[体重过低|体重过低]]<ref name="pmid12647431">{{cite journal | author = Landowski, J | title = [Mirtazapine--an antidepressant] | language = pl | journal = Psychiatria Polska | volume = 36 | issue = 6 Suppl | pages = 125–30 | year = 2002 | pmid = 12647431 | doi = | url = }}</ref><ref name="pmid18001374">{{cite journal | author = Chinuck, RS; Fortnum, H; Baldwin, DR | title = Appetite stimulants in cystic fibrosis: a systematic review | journal = Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association | volume = 20 | issue = 6 | pages = 526–37 |date=December 2007 | pmid = 18001374 | doi = 10.1111/j.1365-277X.2007.00824.x | url = http://dx.doi.org/10.1111/j.1365-277X.2007.00824.x}}</ref><ref name="pmid12647979">{{cite journal | author = Davis, MP; Khawam, E; Pozuelo, L; Lagman, R | title = Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project | journal = Expert Review of Anticancer Therapy | volume = 2 | issue = 4 | pages = 365–76 |date=August 2002 | pmid = 12647979 | doi = 10.1586/14737140.2.4.365 | url = http://www.future-drugs.com/doi/abs/10.1586/14737140.2.4.365?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed}}</ref>
* [[失眠|失眠]]<ref name="pmid9917581">{{cite journal | author = Hartmann, PM | title = Mirtazapine: a newer antidepressant | journal = Am Fam Physician | volume = 59 | issue = 1 | pages = 159–61 |date=January 1999 | pmid = 9917581 | doi = }}</ref><ref name="pmid19374460">{{cite journal | author = Jindal, RD | title = Insomnia in patients with depression: some pathophysiological and treatment considerations | journal = CNS Drugs | volume = 23 | issue = 4 | pages = 309–29 | year = 2009 | pmid = 19374460 | doi = 10.2165/00023210-200923040-00004 | url = http://content.wkhealth.com/linkback/openurl?issn=1172-7047&volume=23&issue=4&spage=309 | access-date = 2015-08-31 | archive-date = 2013-02-09 | archive-url = https://archive.is/20130209093505/http://content.wkhealth.com/linkback/openurl?issn=1172-7047&volume=23&issue=4&spage=309 | dead-url = yes }}</ref>
* [[恶心|恶心]]/[[呕吐|呕吐]]<ref name="pmid12404669">{{cite journal | author = Nutt, DJ | title = Tolerability and safety aspects of mirtazapine | journal = Human Psychopharmacology | volume = 17 Suppl 1 | issue = | pages = S37–41 |date=June 2002 | pmid = 12404669 | doi = 10.1002/hup.388 | url = http://dx.doi.org/10.1002/hup.388}}</ref><ref name="pmid21602639">{{cite journal | author = Li, TC; Shiah, IS; Sun, CJ; Tzang, RF; Huang, KC; Lee, WK | title = Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature | journal = The Journal of ECT | volume = 27 | issue = 2 | pages = 165–7 |date=June 2011 | pmid = 21602639 | doi = 10.1097/YCT.0b013e3181e63346 | url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1095-0680&volume=27&issue=2&spage=165}}</ref><ref name="pmid17587360">{{cite journal | author = Kast, RE; Foley, KF | title = Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects | journal = Eur J Cancer Care (Engl) | volume = 16 | issue = 4 | pages = 351–4 |date=July 2007 | pmid = 17587360 | doi = 10.1111/j.1365-2354.2006.00760.x }}</ref>
* [[瘙痒|瘙痒]]<ref name="pmid12509645">{{cite journal | author = Twycross, R; Greaves, MW; Handwerker, H; et al. | title = Itch: scratching more than the surface | journal = QJM : Monthly Journal of the Association of Physicians | volume = 96 | issue = 1 | pages = 7–26 |date=January 2003 | pmid = 12509645 | doi = 10.1093/qjmed/hcg002| url = http://qjmed.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12509645}}</ref><ref name="pmid16297004">{{cite journal | author = Greaves, MW | title = Itch in systemic disease: therapeutic options | journal = Dermatologic Therapy | volume = 18 | issue = 4 | pages = 323–7 | year = 2005 | pmid = 16297004 | doi = 10.1111/j.1529-8019.2005.00036.x | url = http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1396-0296&date=2005&volume=18&issue=4&spage=323}}</ref>
* [[头痛|头痛]]和[[偏头痛|偏头痛]]<ref name="pmid21602639" /><ref name="pmid15549531">{{cite journal | author = Colombo, B; Annovazzi, PO; Comi, G | title = Therapy of primary headaches: the role of antidepressants | journal = Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | volume = 25 Suppl 3 | issue = | pages = S171–5 |date=October 2004 | pmid = 15549531 | doi = 10.1007/s10072-004-0280-x | url = http://dx.doi.org/10.1007/s10072-004-0280-x}}</ref><ref name="pmid17073214">{{cite journal | author = Tajti, J; Almási, J | title = [Effects of mirtazapine in patients with chronic tension-type headache. Literature review] | language = hu | journal = Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology | volume = 8 | issue = 2 | pages = 67–72 |date=June 2006 | pmid = 17073214 | doi = | url = }}</ref>
{{colend}}

===研究性的===
有过文献报道的使用米氮平进行过实验性治疗的症状包括:
* [[睡眠呼吸暂停|睡眠呼吸暂停]]/[[低呼吸量|低呼吸量]]<ref name="pmid19388881">{{cite journal | author = Kohler, M; Bloch, KE; Stradling, JR | title = Pharmacological approaches to the treatment of obstructive sleep apnoea | journal = Expert Opinion on Investigational Drugs | volume = 18 | issue = 5 | pages = 647–56 |date=May 2009 | pmid = 19388881 | doi = 10.1517/13543780902877674 | url = http://informahealthcare.com/doi/abs/10.1517/13543780902877674%20}}</ref><ref name="pmid18548827">{{cite journal | author = Marshall, NS; Yee, BJ; Desai, AV; Buchanan, PR; Wong, KK; Crompton, R; Melehan, KL; Zack, N; Rao, SG; Gendreau, RM; Kranzler, J; Grunstein, RR | title = Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea | journal = Sleep | volume = 31 | issue = 6 | pages = 824–31 |date=June 2008 | pmid = 18548827 | pmc = 2442407 | doi = }}</ref>
* 不适当的[[性行为|性行为]]和其他由[[自闭症|自闭症]]和其他广泛性发育障碍等导致的继发症状。<ref name="pmid15584771">{{cite journal | author = Masi, G | title = Pharmacotherapy of pervasive developmental disorders in children and adolescents | journal = CNS Drugs | volume = 18 | issue = 14 | pages = 1031–52 | year = 2004 | pmid = 15584771 | doi = 10.2165/00023210-200418140-00006 | url = http://content.wkhealth.com/linkback/openurl?issn=1172-7047&volume=18&issue=14&spage=1031 }}{{dead link|date=2018年4月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name="pmid12589395">{{cite journal | author = Marek, GJ; Carpenter, LL; McDougle, CJ; Price, LH | title = Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders | journal = Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology | volume = 28 | issue = 2 | pages = 402–12 |date=February 2003 | pmid = 12589395 | doi = 10.1038/sj.npp.1300057 | url = http://dx.doi.org/10.1038/sj.npp.1300057}}</ref><ref name="pmid11642476">{{cite journal | author = Posey, DJ; Guenin, KD; Kohn, AE; Swiezy, NB; McDougle, CJ | title = A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders | journal = J Child Adolesc Psychopharmacol | volume = 11 | issue = 3 | pages = 267–77 | year = 2001 | pmid = 11642476 | doi = 10.1089/10445460152595586 }}</ref><ref name="pmid19364298">{{cite journal | author = Coskun, M; Karakoc, S; Kircelli, F; Mukaddes, NM | title = Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder | journal = J Child Adolesc Psychopharmacol | volume = 19 | issue = 2 | pages = 203–6 |date=April 2009 | pmid = 19364298 | doi = 10.1089/cap.2008.020 }}</ref>
* [[抗精神病药|抗精神病药]]导致的[[静坐不能|静坐不能]]<ref name="pmid19378382">{{cite journal | author = Kumar, R; Sachdev, PS | title = Akathisia and second-generation antipsychotic drugs | journal = Current Opinion in Psychiatry | volume = 22 | issue = 3 | pages = 293–99 |date=May 2009 | pmid = 19378382 | doi = 10.1097/YCO.0b013e32832a16da| url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0951-7367&volume=22&issue=3&spage=293}}</ref><ref name="pmid18460588">{{cite journal | author = Hieber, R; Dellenbaugh, T; Nelson, LA | title = Role of mirtazapine in the treatment of antipsychotic-induced akathisia | url = https://archive.org/details/sim_annals-of-pharmacotherapy_2008-06_42_6/page/841 | journal = Annals of Pharmacotherapy | volume = 42 | issue = 6 | pages = 841–6 |date=June 2008 | pmid = 18460588 | doi = 10.1345/aph.1K672 }}</ref>
* [[药物戒断|药物戒断]]、[[药物依赖|药物依赖]]和[[戒毒|戒毒]]<ref>{{cite journal|title=Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside|journal=Pharmacology & Therapeutics|author=Graves, SM; Rafeyan, R; Watts, J; Napier, TC|date=December 2012|volume=136|issue=3|pages=343–353|doi=10.1016/j.pharmthera.2012.08.013|pmid=22960395|pmc=3483434}}</ref>
* [[精神分裂症|精神分裂症]]导致的消极、抑郁和认知障碍。（作为辅助治疗）<ref>{{cite book | isbn = 9789400758056 | title = Polypharmacy in Psychiatry Practice, Volume I | author = Ritsner, MS | year = 2013 | publisher = Springer Science+Business Media Dordrecht | url = http://link.springer.com/book/10.1007/978-94-007-5805-6/  | pages =  }}</ref><ref>{{cite journal|title=Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia|journal=Clinical Schizophrenia & Related Psychoses|publisher=Walsh Medical Media|issn=1935-1232|doi=10.3371/CSRP.VIRE.030813|date=March 2013|pages=1–24|pmid=23491969|author=Vidal, C; Reese, C; Fischer, BA; Chiapelli, J; Himelhoch, S}}</ref>
* 有文献报道，一例伴有视觉幻觉的[[帕金森氏病|帕金森氏病]]精神病患者在使用米氮平后症状有所减轻。<ref>{{cite journal|title=Mirtazapine improves visual hallucinations in Parkinson's disease: a case report|journal=Psychogeriatrics|year=June 2013|volume=13|issue=2|pages=103–107|doi=10.1111/j.1479-8301.2012.00432.x|pmid=23909968|author=Tagai, K; Nagata, T; Shinagawa, S; Tsuno, N; Ozone, M; Nakayama, K}}</ref> 这与近期发现的作用于[[5-HT2A受体|5-HT<sub>2A</sub>受体]]的[[反激动剂|反激动剂]]可以有效地减轻帕金森氏病的精神病症状这个事实相吻合。<ref>{{cite book | isbn = 978-0-470-97948-8 | title = The Maudsley prescribing guidelines in psychiatry | last1 = Taylor | first1 = D |author2=Paton, C; Shitij, K | year = 2012 | publisher = Wiley-Blackwell | location = West Sussex  | pages =  }}</ref>

=== 有效性和耐受性 ===
2010年，NICE发布了治疗抑郁症的指南，其中包括对抗抑郁药的综述。它建议将通用[[选择性5-羟色胺再摄取抑制剂|SSRI]]s作为第一线选择，因为它们“与其他抗抑郁药同样有效并且具有有利的风险-效益比”。<ref>[https://www.ncbi.nlm.nih.gov/books/NBK63751/#ch10.s159 Pharmacological Interventions: 10.14. Clinical Practice Recommendations]. National Collaborating Centre for Mental Health/British Psychological Society. 2010.</ref>关于米氮平，它发现：“米氮平与其他抗抑郁药在任何疗效指标上没有差异，尽管在达到缓解方面，米氮平似乎具有统计学但不具有临床意义的优势。此外，米氮平具有优于[[选择性5-羟色胺再摄取抑制剂|SSRI]]s的统计学优势。就减少抑郁症状而言，这种差异在临床上并不重要。然而，有强有力的证据表明服用米氮平的患者由于副作用而不太可能提早离开治疗，尽管对于报告副作用的患者不是这种情况或因任何原因提早离开治疗。“<ref>[https://www.ncbi.nlm.nih.gov/books/NBK63751/#ch10.s68 ''Pharmacological Interventions: Third-Generation Antidepressants: 10.8.3. Mirtazapine''.] National Collaborating Centre for Mental Health/British Psychological Society. 2010.</ref>]

2011年Cochrane评价将米氮平与其他抗抑郁药进行了比较，结果发现，虽然它对患者的起效较快（在第2周时），但在第6周时它与其他的抗抑郁药大致相同。<ref name="#1">Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA (December 2011). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158430 "Mirtazapine versus other antidepressive agents for depression"]. ''The Cochrane Database of Systematic Reviews'' (12): CD006528. doi:10.1002/14651858.CD006528.pub2. PMC 4158430. <nowiki>PMID 22161405</nowiki>.</ref>

一项针对抗抑郁药和睡眠的2012年评论发现，在许多因抑郁引起[[睡眠障碍|睡眠障碍]]的患者中，米氮平减少了入睡所需的时间并提高了睡眠质量，但在某些人中，它会扰乱睡眠，有8％至28％的人会有[[不寧腿綜合症|不安腿综合征]]，并且它在极少数情况下导致[[快速動眼期|REM睡眠]]行为障碍。

2018年有项系统评价和网络荟萃分析比较了12种抗抑郁药物的疗效和耐受性，结果显示米氮平是头对头研究中最有效的抗抑郁药之一。<ref>Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR (April 2018). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889788 "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis"]. ''Lancet''. '''391''' (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. <nowiki>PMID 29477251</nowiki>.</ref>

在第1周之后，相较于SSRI，米氮平有着更快的起效时间。<ref>Thompson C (June 2002). [https://dx.doi.org/10.1002/hup.386 "Onset of action of antidepressants: results of different analyses"]. ''Human Psychopharmacology''. 17 Suppl 1: S27–32. doi:10.1002/hup.386. <nowiki>PMID 12404667</nowiki>.</ref><ref name="#2">Taylor D, Paton C, Shitij K (2012). ''Maudsley Prescribing Guidelines in Psychiatry'' (11th ed.). West Sussex: Wiley-Blackwell. ISBN 978-0-47-097948-8.</ref>

== 副作用 ==
2011年Cochrane评价发现，与其他抗抑郁药相比，它更容易引起体重增加和[[嗜睡症|嗜睡]]，但它比[[三环类抗抑郁药|三环类抗抑郁药]]引起震颤的可能性更小，并且比SSRIs更不可能引起恶心和性功能障碍。<ref name="#1"/>

米氮平不被认为存在很多副作用的风险，这些副作用通常和其他抗抑郁药，例如SSRI，有关，并且当他们一起使用时可以改善某些副作用。这些不良反应包括[[食欲不振|食欲减退]]，体重减轻，[[失眠|失眠]]，[[恶心|恶心]]和[[呕吐|呕吐]]，[[腹瀉|腹泻]]，[[尿瀦留|尿潴留]]，[[体温过高|体温升高]]，出汗过多，瞳孔扩张和[[性功能障碍|性功能障碍]]。<ref name=":0">Anttila SA, Leinonen EV (2001). "A review of the pharmacological and clinical profile of mirtazapine". ''CNS Drug Rev''. '''7''' (3): 249–64. doi:10.1111/j.1527-3458.2001.tb00198.x. <nowiki>PMID 11607047</nowiki>.</ref><ref name=":10">Fawcett J, Barkin RL (December 1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". ''Journal of Affective Disorders''. '''51''' (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. <nowiki>PMID 10333982</nowiki>.</ref>

一般地，有些抗抑郁药，例如SSRI，会自相矛盾地加剧一些人的抑郁或焦虑或自杀意念。<ref>Möller HJ (December 2006). "Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review". ''European Archives of Psychiatry and Clinical Neuroscience''. '''256''' (8): 476–96. doi:10.1007/s00406-006-0689-8. <nowiki>PMID 17143567</nowiki>.</ref>尽管米氮平具有镇静作用，但据信也有能力做到这一点，所以在美国和其他一些国家，它带有黑框标签来警告这些潜在的影响。

2000年发表的一份病例报告指出，米氮平可以抵消[[可乐定|可乐定]]的作用，导致血压升高。<ref>Abo-Zena RA, Bobek MB, Dweik RA (April 2000). "Hypertensive urgency induced by an interaction of mirtazapine and clonidine". ''Pharmacotherapy''. '''20''' (4): 476–8. doi:10.1592/phco.20.5.476.35061. <nowiki>PMID 10772378</nowiki>.</ref>

=== 不良反应发生率<ref>《米氮平片说明书》，山德士（中国）制药有限公司。</ref> ===
非常常见（≥1/10）

* 体重增加
* 食欲增加
* 嗜睡
* 镇静作用
*[[口乾|口干]]

常见（≥1/100~＜1/10）

* 梦异常
* 意思混乱
*[[焦虑症|焦虑]]
* 失眠

不常见（≥1,000~<1/100）

*[[梦魇|梦魇]]
*[[躁狂症|躁狂症]]
*[[兴奋|兴奋]]
*[[幻觉|幻觉]]
* 精神运动性坐立不安（包括[[静坐不能|静坐不能]]、运动机能亢进）
* 感觉异常
*[[不寧腿綜合症|不宁腿症状]]
*[[低血壓|低血压]]
* 口腔感觉减退

罕见（≥1/10,000~>1/1,000）

* 肌痉挛
* 血清氨基转移酶增加

频率不详

*[[骨髓抑制|骨髓抑制]]（[[粒细胞|粒细胞]]减少、粒细胞缺乏、再生性贫血以及[[血小板|血小板]]减少症）
*[[嗜酸性粒细胞增多症|嗜酸性粒细胞增多]]
*[[低血鈉症|低钠血症]]
* 自杀意图
* 自杀行为
*[[驚厥|惊厥]]（发作）
*[[血清素综合症|5-羟色胺综合征]]
* 口腔感觉异常
* 口唇[[水肿|水肿]]
*[[史蒂芬斯－強森症候群|Stevens-Johnson综合征]]
* 大疱性皮炎
* 多形性红斑
* 中毒性表皮坏死

=== 停药 ===
米氮平和其他抗抑郁药可能在停止服用后引发停药综合征。<ref name=":0" /><ref name=":1">Benazzi F (June 1998). "Mirtazapine withdrawal symptoms". Canadian Journal of Psychiatry. Revue canadienne de psychiatrie. 43 (5): 525. <nowiki>PMID 9653542</nowiki>.[[wikipedia:可靠來源_(醫學)|<sup>[不可靠的醫學來源?]</sup>]]</ref><ref>Blier P (2001). "Pharmacology of rapid-onset antidepressant treatment strategies". ''The Journal of Clinical Psychiatry''. 62 Suppl 15: 12–7. <nowiki>PMID 11444761</nowiki>.</ref>建议逐渐缓慢减少剂量，以尽量减少停药综合征。<ref>Vlaminck JJ, van Vliet IM, Zitman FG (March 2005). "[Withdrawal symptoms of antidepressants]". ''Nederlands Tijdschrift Voor Geneeskunde'' (in Dutch and Flemish). '''149''' (13): 698–701. <nowiki>PMID 15819135</nowiki>.</ref>突然停止米氮平治疗的后果可能包括抑郁，[[焦虑症|焦虑]]，[[耳鸣|耳鸣]]，[[惊恐发作|惊恐发作]]，[[眩暈_(醫學)|眩晕]]，精神运动激动，[[易怒|易怒]]，[[食欲减退|食欲减退]]，[[失眠|失眠]]，[[腹泻|腹泻]]，[[恶心|恶心]]，[[呕吐|呕吐]]，[[流感|流感]]类似[[过敏|过敏]]和[[瘙痒症|瘙痒症]]，[[头痛|头痛]]，有时会有[[轻度狂躁|轻度躁狂]]或[[躁狂症|躁狂症]]。<ref name=":1" /><ref><sup>Berigan TR (June 2001). "Mirtazapine-Associated Withdrawal Symptoms: A Case Report". Primary Care Companion to the Journal of Clinical Psychiatry. 3 (3): 143. doi:10.4088/PCC.v03n0307a. PMC 181176. <nowiki>PMID 15014614</nowiki>.[[wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</sup></ref><ref><sup>Klesmer J, Sarcevic A, Fomari V (August 2000). "Panic attacks during discontinuation of mirtazepine". Canadian Journal of Psychiatry. Revue canadienne de psychiatrie. 45 (6): 570–1. <nowiki>PMID 10986577</nowiki>.[[wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</sup></ref><ref>MacCall C, Callender J (October 1999). "Mirtazapine withdrawal causing hypomania". The British Journal of Psychiatry. 175 (4): 390. doi:10.1192/bjp.175.4.390a. <nowiki>PMID 10789310</nowiki>.[[wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</ref><ref>Ali S, Milev R (May 2003). "Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature". ''Canadian Journal of Psychiatry. Revue canadienne de psychiatrie''. '''48''' (4): 258–64. doi:10.1177/070674370304800410. <nowiki>PMID 12776393</nowiki>.</ref>

== 药物相互作用 ==
与细胞色素（[[细胞色素P450|CYP]]）[[细胞色素P450|P450同工酶]][[CYP1A2|CYP1A2]]，[[CYP2D6|CYP2D6]]和/或[[CYP3A4|CYP3A4]]的抑制剂或诱导剂同时使用可导致米氮平的浓度改变，因为这些是负责其代谢的主要酶。<ref name=":2">Timmer CJ, Sitsen JM, Delbressine LP (June 2000). "Clinical pharmacokinetics of mirtazapine". Clinical Pharmacokinetics. 38 (6): 461–74. doi:10.2165/00003088-200038060-00001. <nowiki>PMID 10885584</nowiki>.</ref><ref>Anttila SA, Leinonen EV (2001). "A review of the pharmacological and clinical profile of mirtazapine". ''CNS Drug Rev''. '''7''' (3): 249–64. doi:10.1111/j.1527-3458.2001.tb00198.x. <nowiki>PMID 11607047</nowiki>.</ref>例如，已知[[氟西汀|氟西汀]]和[[帕罗西汀|帕罗西汀]]（这些酶的抑制剂）适度增加米氮平水平，而[[卡马西平|卡马西平]]（一种诱导剂）可显著降低米氮平水平。<ref name=":2" />据报道，在肝功能损害和中度肾功能损害的人群中，米氮平口服清除率降低约30％；而严重肾功能损害患者的口服清除率减少50％。<ref name=":2" />

根据制造商提供的信息，米氮平不应在任何[[单胺氧化酶抑制剂|单胺氧化酶抑制剂]]（[[单胺氧化酶抑制剂|MAOI]]）停用后两周内开始使用；同样，MAOI不应在停用米氮平后两周内给药。<ref>[https://www.drugs.com/monograph/mirtazapine.html "Mirtazapine Monograph for Professionals - Drugs.com".]</ref>米氮平与[[选择性5-羟色胺再摄取抑制剂|SSRI]]，[[5-羟色胺和去甲肾上腺素再摄取抑制剂|SNRI]]或[[三环类抗抑郁药|TCA]]联合作为增强策略被认为是相对安全的，而且通常用于治疗。<ref>Fawcett J, Barkin RL (December 1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". ''Journal of Affective Disorders''. '''51''' (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. <nowiki>PMID 10333982</nowiki>.</ref>[[文拉法辛|文拉法辛]]和米氮平的组合，有时被称为“加州火箭燃料”。<ref>Stahl SM (2008). [http://stahlonline.cambridge.org/prescribers_drug.jsf?page=0521683505c57_p325-330.html.therapeutics&name=Mirtazapine&title=Therapeutics Stahl's Essential Psychopharmacology Online: Print and Online.] Cambridge, UK: Cambridge University Press. ISBN 0-521-74609-4.</ref><ref>Silva J, Mota J, Azevedo P (March 2016). "California rocket fuel: And what about being a first line treatment?". ''European Psychiatry''. '''33''': S551. doi:10.1016/j.eurpsy.2016.01.2033.</ref>已知在氟西汀和米氮平同时给药的情况下可能发生[[血清素综合症|5-羟色胺综合征]]。

== 过量 ==
如果服用过量，米氮平被认为是相对安全的<ref name="#2"/>，尽管过量服用的毒性比大多数SSRIs（[[西酞普兰|西酞普兰]]除外）略高。<ref>White N, Litovitz T, Clancy C (December 2008). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550116/pdf/13181_2009_Article_BF03161207.pdf "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type"] {{Wayback|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550116/pdf/13181_2009_Article_BF03161207.pdf |date=20200408110317 }} (PDF). ''Journal of Medical Toxicology''. '''4''' (4): 238–50. doi:10.1007/bf03161207. PMC 3550116. <nowiki>PMID 19031375</nowiki>.</ref>与三环类抗抑郁药不同，米氮平在最大推荐剂量的7至22倍时未显示出明显的心血管不良反应。<ref>Fawcett J, Barkin RL (December 1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". Journal of Affective Disorders. 51 (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. <nowiki>PMID 10333982</nowiki>.</ref>与三环类抗抑郁药相比，过量服用标准剂量30至50倍的病例报告称药物相对无毒。<ref><sup>Holzbach R, Jahn H, Pajonk FG, Mähne C (November 1998). "Suicide attempts with mirtazapine overdose without complications". Biological Psychiatry. 44 (9): 925–6. doi:10.1016/S0006-3223(98)00081-X. <nowiki>PMID 9807651</nowiki>.[[Wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</sup></ref><ref>Retz W, Maier S, Maris F, Rösler M (November 1998). "Non-fatal mirtazapine overdose". International Clinical Psychopharmacology. 13 (6): 277–9. doi:10.1097/00004850-199811000-00007. <nowiki>PMID 9861579</nowiki>.[[Wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</ref>

据报道，有12人死于米氮平过量。<ref>Nikolaou P, Dona A, Papoutsis I, Spiliopoulou C, Maravelias C. "Death Due to Mirtazapine Overdose". in "Abstracts of the XXIX International Congress of the European Association of Poison Centres and Clinical Toxicologists, May 12–15, 2009, Stockholm, Sweden". Clinical Toxicology. 47 (5): 436–510. 2009. doi:10.1080/15563650902952273.</ref><ref>Baselt, RC (2008). ''Disposition of Toxic Drugs and Chemicals in Man'' (8th ed.). Foster City, CA: Biomedical Publications. pp. 1045–7. ISBN 978-0-9626523-7-0.</ref>米氮平的致命毒性指数（每百万处方死亡人数）为3.1（95％CI：0.1至17.2）。这类似于用SSRIs观察到的情况。<ref><sup>Buckley NA, McManus PR (December 2002). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137809 "Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data"]. BMJ. 325 (7376): 1332–3. doi:10.1136/bmj.325.7376.1332. PMC 137809. <nowiki>PMID 12468481</nowiki>.[[Wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</sup></ref>

== 药理学 ==

=== 药效学 ===
{{See also |抗抑郁药|四环类抗抑郁药}}
{| class="wikitable floatright"
|+米氮平<ref>Roth, BL; Driscol, J. [https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=mirtazepine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query "PDSP K<sub>i</sub> Database"]. ''Psychoactive Drug Screening Program (PDSP)''. University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.</ref>
!Ki(nm)
!物种
!来源
!参考
|-
|[[血清素轉運體|SERT]]
|>10,000
|人类
|<ref name=":3">Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". ''Eur. J. Pharmacol''. '''340'''(2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. <nowiki>PMID 9537821</nowiki>.</ref><ref name=":4">Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE (2006). "Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist". ''Bioorg. Med. Chem''. '''14''' (13): 4526–34. doi:10.1016/j.bmc.2006.02.029. <nowiki>PMID 16517171</nowiki>.</ref>
|-
|[[去甲腎上腺素轉運體|NET]]
|≥4,600
|人类
|<ref name=":5">Gillman PK (2007). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014120 "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated"]. ''Br. J. Pharmacol''. '''151''' (6): 737–48. doi:10.1038/sj.bjp.0707253. PMC 2014120. <nowiki>PMID 17471183</nowiki>.</ref><ref name=":3" />
|-
|[[多巴胺转运体|DAT]]
|>10,000
|人类
|<ref>Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". ''Eur. J. Pharmacol''. '''340'''(2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. <nowiki>PMID 9537821</nowiki>.</ref><ref name=":6">Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE (2006). "Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist". ''Bioorg. Med. Chem''. '''14''' (13): 4526–34. doi:10.1016/j.bmc.2006.02.029. <nowiki>PMID 16517171</nowiki>.</ref>
|-
|[[5-HT1A|5-HT<sub>1A</sub>]]
|3,330~5,010
|人类
|<ref name=":0" /><ref name=":6" />
|-
|[[5-HT1B|5-HT<sub>1B</sub>]]
|3,534~12,600
|人类
|<ref name=":0" /><ref name=":4" />
|-
|[[5-HT1D|5-HT<sub>1D</sub>]]
|794-5,010
|人类
|<ref name=":0" /><ref name=":4" />
|-
|[[5-HT1E|5-HT<sub>1E</sub>]]
|728
|人类
|<ref name=":4" />
|-
|[[5-HT1F|5-HT<sub>1F</sub>]]
|583
|人类
|<ref name=":4" />
|-
|[[5-HT2受體|'''5-HT<sub>2A</sub>''']]
|'''6.3~69'''
|人类
|<ref name=":0" /><ref name=":4" /><ref name=":7">Fernández J, Alonso JM, Andrés JI, Cid JM, Díaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA (2005). "Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents". ''J. Med. Chem''. '''48'''(6): 1709–12. doi:10.1021/jm049632c. <nowiki>PMID 15771415</nowiki>.</ref>
|-
|[[5-HT2B受體|5-HT<sub>2B</sub>]]
|200
|人类
|<ref name=":0" />
|-
|[[5-HT2受體|'''5-HT<sub>2C</sub>''']]
|'''8.9~39'''
|人类
|<ref name=":0" /><ref name=":4" /><ref name=":7" />
|-
|'''[[5-HT3|5-HT<sub>3</sub>]]'''
|'''7.9'''
|人类
|<ref name=":0" />
|-
|[[5-HT4受體|5-HT<sub>4L</sub>]]
|>10,000
|人类
|<ref name=":4" />
|-
|[[5-HT5A|5-HT<sub>5A</sub>]]
|670
|人类
|<ref name=":4" />
|-
|[[5-HT6|5-HT<sub>6</sub>]]
|ND
|ND
|ND
|-
|[[5-HT7|5-HT<sub>7</sub>]]
|265
|人类
|<ref name=":4" /><ref name=":7" />
|-
|[[Α1A|α<sub>1A</sub>]]
|316~1,815
|人类
|<ref name=":4" />
|-
|[[Α2A|'''α<sub>2A</sub>''']]
|'''20'''
|人类
|<ref name=":4" /><ref name=":7" />
|-
|[[Α2B|'''α<sub>2B</sub>''']]
|'''88'''
|人类
|<ref name=":4" />
|-
|[[Α2C|'''α<sub>2C</sub>''']]
|'''18'''
|人类
|<ref name=":4" /><ref name=":7" />
|-
|[[Β受体|β]]
|>10,000
|人类
|<ref name=":4" />
|-
|[[多巴胺受体D1|D<sub>1</sub>]]
|~4167
|大鼠
|<ref name=":7" />
|-
|[[多巴胺受體D2|D<sub>2</sub>]]
|>5,454
|人类
|<ref name=":4" /><ref name=":7" />
|-
|[[多巴胺受体D3|D<sub>3</sub>]]
|5723
|人类
|<ref name=":4" /><ref name=":7" />
|-
|[[多巴胺受体D4|D<sub>4</sub>]]
|2,518
|人类
|<ref name=":4" />
|-
|[[H1受体|'''H<sub>1</sub>''']]
|'''0.14~1.6'''
|人类
|<ref name=":0" /><ref name=":4" /><ref name=":7" /><ref name=":8">Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". ''Naunyn Schmiedebergs Arch. Pharmacol''. '''385''' (2): 145–70. doi:10.1007/s00210-011-0704-0. <nowiki>PMID 22033803</nowiki>.</ref>
|-
|[[H2受体|H<sub>2</sub>]]
|>10,000
|大鼠
|<ref name=":8" /><ref name=":9">de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM (April 1988). "Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers". ''Neuropharmacology''. '''27'''(4): 399–408. doi:10.1016/0028-3908(88)90149-9. <nowiki>PMID 3419539</nowiki>.</ref>
|-
|[[H3受体|H<sub>3</sub>]]
|83,200
|人类
|<ref name=":9" />
|-
|[[H4受体|H<sub>4</sub>]]
|>100,000
|人类
|<ref name=":9" />
|-
|[[蕈毒鹼型乙醯膽鹼受體|mAch]]
|670
|人类
|<ref name=":0" /><ref name=":5" />
|-
|[[鈉離子通道|VGSC]]
|6,905
|大鼠
|<ref name=":4" />
|-
|[[钙离子通道|VDCC]]
|>10,000
|大鼠
|<ref name=":4" />
|}

米氮平有时被分类为去甲肾上腺素和特异性五羟色胺能能抗抑郁药（NaSSA），<ref name=":0" />尽管支持此分类的证据并不可靠。<ref name=":11">Gillman PK (2006). "A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status". ''Hum Psychopharmacol''. '''21''' (2): 117–25. doi:10.1002/hup.750. <nowiki>PMID 16342227</nowiki>.</ref>米氮平有抗去甲肾上腺素、[[组胺|组胺]]和5-羟色胺受体的功效。<ref name=":12">Frazer A (1997). "Pharmacology of antidepressants". ''J Clin Psychopharmacol''. 17 Suppl 1: 2S–18S. doi:10.1097/00004714-199704001-00002. <nowiki>PMID 9090573</nowiki>.</ref><ref name=":0" />它特别是肾上腺素α <sub>2A</sub> ，α<sub>2B</sub>，和α<sub>2C</sub>受体、组胺H<sub>1</sub>受体和5-羟色胺5-HT<sub>2A</sub>、5-HT<sub>2C</sub>和5-HT<sub>3</sub>的[[受体拮抗剂|拮抗剂]]或[[反激动剂|反向激动剂]]。<ref name=":0" /><ref name=":12" />不同于许多其他的抗抑郁药，它不抑制5-羟色胺、去甲肾上腺素或[[多巴胺|多巴胺]]的再摄取，也不抑制[[单胺氧化酶|单胺氧化酶]]。<ref>Fisar Z, Hroudová J, Raboch J (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers". ''Neuro Endocrinology Letters''. '''31''' (5): 645–56. <nowiki>PMID 21200377</nowiki>.</ref>同多数抗抑郁药类似，米氮平的[[抗胆碱能|抗胆碱能]]、阻断[[鈉離子通道|钠离子通道]]或阻断[[钙通道|钙离子通道]]的效应很弱甚至没有。然而在过量食用时，米氮平具有更好的耐受性和低毒性。米氮平是TCA或[[四环类抗抑郁药|TeCA]]中最有效的H<sub>1</sub>受体拮抗剂，拮抗H<sub>1</sub>受体是米氮平最强的活性，它在低剂量下为选择性H<sub>1</sub>受体拮抗剂。<ref name=":0" /><ref name=":4" />

米氮平的(S)-(+)对映体负责5-羟色胺5-HT<sub>2A</sub>和5-HT<sub>2C</sub>的拮抗作用，<ref name="MD" />(R)-(-)对映体负责对5-HT<sub>3</sub>受体的拮抗作用。虽然(R)-(-)是很强的组胺H<sub>1</sub>受体的拮抗剂，两种对映体都参与了对组胺H<sub>1</sub>受体和肾上腺素α<sub>2</sub>受体的拮抗作用。

虽然没有临床意义，已经发现米氮平在高浓度的情况下是κ[[阿片样肽受体|阿片样受体]]的[[部分激动剂|部分激动剂]]<ref>Olianas MC, Dedoni S, Onali P (November 2012). "The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors". ''British Journal of Pharmacology''. '''167''' (6): 1329–41. doi:10.1111/j.1476-5381.2012.02078.x. PMC 3504997. <nowiki>PMID 22708686</nowiki>.</ref>（EC<sub>50</sub>=7.2nm）。

==== α<sub>2</sub>肾上腺素受体 ====
作为肾上腺素α<sub>2</sub>受体的拮抗剂，其功能主要是由于抑制自受体和异受体，提高去甲肾上腺素和5-羟色胺能的神经传递，特别是中央 5-HT<sub>1A</sub>受体介导的中缝背核和[[海马体|海马]]的[[神经递质|神经递质]]的传导；因此，米氮平的分类为NaSSA。间接地增强α<sub>1</sub>受体介导的5-羟色胺细胞放电和抑制、直接阻断5-羟色胺神经元上的异受体会增加细胞外5-羟色胺的浓度。<ref name=":0" /><ref name="pmid10446735" /><ref><sup>De Boer T, Nefkens F, Van Helvoirt A (February 1994). "The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo". European Journal of Pharmacology. 253 (1–2): R5–6. doi:10.1016/0014-2999(94)90778-1. <nowiki>PMID 7912194</nowiki>.[[Wikipedia:可靠來源_(醫學)|[不可靠的醫學來源?]]]</sup></ref><ref name=":13">Berendsen HH, Broekkamp CL (October 1997). "Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine". Psychopharmacology. 133 (3): 275–82. doi:10.1007/s002130050402. <nowiki>PMID 9361334</nowiki>.</ref><ref>Nakayama K, Sakurai T, Katsu H (April 2004). "Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation". Brain Research Bulletin. 63 (3): 237–41. doi:10.1016/j.brainresbull.2004.02.007. <nowiki>PMID 15145142</nowiki>.[[Wikipedia:可靠來源_(醫學)|[不可靠的医学来源?]]]</ref>因此，米氮平被认为是5-HT<sub>1A</sub>受体的“间接[[激动剂|激动剂]] ”。<ref name=":13" />中枢5-HT<sub>1A</sub>受体的活动增加被认为是大多数抗抑郁药物功效的主要原理。<ref>Blier P, Abbott FV (January 2001). "Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain" (PDF). Journal of Psychiatry & Neuroscience. 26 (1): 37–43. PMC 1408043. <nowiki>PMID 11212592</nowiki>.</ref>

====[[5-HT2受體|5-HT<sub>2</sub>]]和5-HT<sub>3</sub>受体 ====
对5-HT<sub>2</sub>受体亚族的拮抗作用和对5-HT<sub>2C</sub>受体的反向激动作用似乎是米氮平治疗抑郁的机理之一。<ref>Millan MJ (2005). "Serotonin 5-HT<sub>2C</sub> receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies". ''Thérapie''. '''60''' (5): 441–60. doi:10.2515/therapie:2005065. <nowiki>PMID 16433010</nowiki>.</ref><ref>Dekeyne A, Millan MJ (April 2009). "Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization". Psychopharmacology. 203 (2): 329–41. doi:10.1007/s00213-008-1259-8. <nowiki>PMID 18709360</nowiki>.</ref>米氮平能增加[[前額葉皮質|前额叶皮质]]中的多巴胺能，对大鼠的研究结果表明，阻断α<sub>2</sub>受体和5-HT<sub>2C</sub>受体能对大鼠的此区域对多巴胺的释放去抑制。<ref>Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (March 2000). "Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram". The European Journal of Neuroscience. 12 (3): 1079–95. doi:10.1046/j.1460-9568.2000.00982.x. <nowiki>PMID 10762339</nowiki>.</ref>米氮平对5-HT<sub>2A</sub>受体的拮抗作用对焦虑、失眠和[[性功能|性功能]]有改进。<ref name=":0" />已证明米氮平可以降低人类和各种动物的寻药行为。它也正在被研究对[[物質濫用|物质滥用]]的行为，以减少戒断效应和提高缓解率。<ref>Graves SM, Napier TC (June 2012). "SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats". ''BMC Neuroscience''. '''13''' (1): 65. doi:10.1186/1471-2202-13-65. PMC 3441362. <nowiki>PMID 22697313</nowiki>.</ref><ref name=":14">Rose ME, Grant JE (2008). "Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions". ''Annals of Clinical Psychiatry''. '''20''' (3): 145–55. doi:10.1080/10401230802177656. <nowiki>PMID 18633741</nowiki>.</ref><ref name=":15">Brackins T, Brahm NC, Kissack JC (December 2011). "Treatments for methamphetamine abuse: a literature review for the clinician". ''Journal of Pharmacy Practice''. '''24''' (6): 541–50. doi:10.1177/0897190011426557. <nowiki>PMID 22095579</nowiki>.</ref><ref name=":16">Brensilver M, Heinzerling KG, Shoptaw S (September 2013). "Pharmacotherapy of amphetamine-type stimulant dependence: an update". ''Drug and Alcohol Review''. '''32''' (5): 449–60. doi:10.1111/dar.12048. PMC 4251965. <nowiki>PMID 23617468</nowiki>.</ref>

由于对5-HT<sub>3</sub>受体的拮抗作用，米氮平与批准的止吐药[[昂丹司琼|昂丹司琼]]有着共同的作用，它可显著改善病人的恶心、呕吐、[[腹瀉|腹泻]]和[[肠易激综合征|肠易激综合征]]的症状。<ref>Kast RE (September 2001). "Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy". ''Supportive Care in Cancer''. '''9'''(6): 469–70. doi:10.1007/s005200000215. <nowiki>PMID 11585276</nowiki>.</ref>米氮平可作为一种廉价的止吐药以替代昂丹司琼。<ref>Kast RE, Foley KF (July 2007). "Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT<sub>3</sub> antagonists with good antinausea effects". ''European Journal of Cancer Care''. '''16''' (4): 351–4. doi:10.1111/j.1365-2354.2006.00760.x. <nowiki>PMID 17587360</nowiki>.</ref>在一些研究中，在一些研究中，也发现米氮平对5-HT<sub>3</sub>受体的阻断可以改善焦虑并有效治疗[[物質依賴|物质依赖]]。与物质滥用咨询相结合，米氮平成功地减少了对冰毒依赖的个体对冰毒的使用。<ref>Costall B, Naylor RJ, Tyers MB (1990). "The psychopharmacology of 5-HT<sub>3</sub> receptors". ''Pharmacology & Therapeutics''. '''47''' (2): 181–202. doi:10.1016/0163-7258(90)90086-H. <nowiki>PMID 2203069</nowiki>.</ref><ref name=":14" /><ref name=":15" /><ref name=":16" />与米氮平相比，SSRIs，[[SNRIs|SNRIs]]，MAOIs和一些TCAs增加了5-HT<sub>2A</sub>，5-HT<sub>2C</sub>和5-HT<sub>3</sub>受体的一般活性，造成负面结果和副作用，其中最突出的包括[[厌食|厌食]]、失眠和[[性功能障碍|性功能障碍]]（丧失主动的[[性欲|性欲]]、[[性快感|性快感]]缺失）以及恶心和腹泻等等。因此，它通常与这些药物结合使用，以减少其副作用，并产生更强的抗抑郁作用。<ref name=":10" /><ref>Caldis EV, Gair RD (October 2004). "Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors". ''Canadian Journal of Psychiatry. Revue canadienne de psychiatrie''. '''49''' (10): 707. doi:10.1177/070674370404901014. <nowiki>PMID 15560319</nowiki>.</ref>

米氮平不具有5-羟色胺能活性，不会引起5-羟色胺能副作用或[[血清素综合症|5-羟色胺综合征]]。<ref name=":17">Gillman PK (June 2006). "A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action". ''Biological Psychiatry''. '''59''' (11): 1046–51. doi:10.1016/j.biopsych.2005.11.016. <nowiki>PMID 16460699</nowiki>.</ref><ref name=":11" />这与其不是5-羟色胺[[再攝取抑制劑|再摄取抑制剂]]或MAOI，也不是5-羟色胺受体激动剂的事实一致。<ref name=":11" /><ref name=":17" />没有关于单独使用米氮平的5-羟色胺综合征的报道，并且未发现米氮平过量引起5-羟色胺综合征。<ref name=":17" /><ref name=":11" /><ref>Berling I, Isbister GK (2014). "Mirtazapine overdose is unlikely to cause major toxicity". Clin Toxicol. 52 (1): 20–4. doi:10.3109/15563650.2013.859264. PMC 3894718. <nowiki>PMID 24228948</nowiki>.</ref>但是，有一些案例报告米氮平与SSRIs等5-羟色胺能药物联合应用引起5-羟色胺综合征，尽管这些报道非常罕见，并不一定暗示米氮平是致病因素。<ref name=":11" /><ref>Freijo Guerrero J, Tardón Ruiz de Gauna L, Gómez JJ, Aguilera Celorrio L (2009). "[Serotonin syndrome after administration of mirtazapine in a critical care unit]". Rev Esp Anestesiol Reanim (in Spanish; Castilian). 56 (8): 515–6. <nowiki>PMID 19994622</nowiki>.</ref><ref>Butler MC, Di Battista M, Warden M (2010). "Sertraline-induced serotonin syndrome followed by mirtazapine reaction". ''Prog. Neuropsychopharmacol. Biol. Psychiatry''. '''34''' (6): 1128–9. doi:10.1016/j.pnpbp.2010.04.015. <nowiki>PMID 20430060</nowiki>.</ref><ref>Decoutere L, De Winter S, Vander Weyden L, Spriet I, Schrooten M, Tournoy J, Fagard K (2012). "A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge". ''Int J Clin Pharm''. '''34''' (5): 686–8. doi:10.1007/s11096-012-9666-7. <nowiki>PMID 22752315</nowiki>.</ref><ref>Ansermot N, Hodel PF, Eap CB (2014). "Serotonin toxicity after addition of mirtazapine to escitalopram". ''J Clin Psychopharmacol''. '''34''' (4): 540–1. doi:10.1097/JCP.0000000000000170. <nowiki>PMID 24977717</nowiki>.</ref><ref>Wu CS, Tong SH, Ong CT, Sung SF (2015). "Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report". ''Acta Neurol Taiwan''. '''24''' (4): 117–21. <nowiki>PMID 27333965</nowiki>.</ref>在MAOI中加入米氮平不会引起5-羟色胺综合征，并被认为是一种安全的组合。<ref name=":11" /><ref name=":17" />此外，米氮平实际上可用于治疗5-羟色胺综合征，至少有一篇文章发现它可有效地解决该综合征。<ref name=":11" /><ref>Hoes MJ, Zeijpveld JH (1996). "Mirtazapine as treatment for serotonin syndrome". ''Pharmacopsychiatry''. '''29''' (2): 81. doi:10.1055/s-2007-979550. <nowiki>PMID 8741027</nowiki>.</ref><ref>Shioda K, Nisijima K, Yoshino T, Kato S (2010). "Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome". Neurosci. Lett. 482 (3): 216–9. doi:10.1016/j.neulet.2010.07.039. <nowiki>PMID 20655983</nowiki>.</ref>这是按照5-HT<sub>2A</sub>受体是导致5-羟色胺综合征的主要受体（而5-HT<sub>1A</sub>受体似乎是保护性的）。<ref name=":11" /><ref name=":17" />米氮平是一种有效的5-HT<sub>2A</sub>受体拮抗剂，而赛庚啶是一种具有这种特性的药物，可介导5-羟色胺综合征的恢复，并且在临床上已成熟，可作为对抗它的解毒剂。<ref name=":11" /><ref>qbal MM, Basil MJ, Kaplan J, Iqbal MT (2012). "Overview of serotonin syndrome". ''Ann Clin Psychiatry''. '''24''' (4): 310–8. <nowiki>PMID 23145389</nowiki>.</ref>

==== H<sub>1</sub>受体 ====
米氮平是一种非常强的H<sub>1</sub>受体反向激动剂，因此，它可以引起强大的镇静和催眠作用。<ref name=":0" />米氮平于健康志愿者的单15毫克剂量已被发现导致在H<sub>1</sub>受体的80％以上的占用并诱导强烈的嗜睡。<ref>Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Iwata R, Matsuoka H, Yanai K (2013). "Histamine H₁ receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers". ''Psychopharmacology''. '''230'''(2): 227–34. doi:10.1007/s00213-013-3146-1. <nowiki>PMID 23728612</nowiki>.</ref>但是，经过长时间的慢性治疗，H<sub>1</sub>会脱敏，并且抗组胺能的效应变得更耐受。许多患者也可能在晚上服用以避免这种影响，这似乎是对抗它们的有效策略。阻断H<sub>1</sub>受体可以改善先前存在的患病个体的[[过敏|过敏]]、[[瘙痒症|瘙痒]]、恶心和失眠。然而，它也可能有助于增加体重。与H<sub>1</sub>受体相反，米氮平仅对[[蕈毒鹼型乙醯膽鹼受體|毒蕈碱乙酰胆碱受]]体仅具有低亲和力，尽管在临床实践中有时仍会出现口干、[[便秘|便秘]]和[[瞳孔散大|瞳孔散大]]等[[抗胆碱能|抗胆碱能]]副作用。<ref>Burrows GD, Kremer CM (April 1997). "Mirtazapine: clinical advantages in the treatment of depression". Journal of Clinical Psychopharmacology. 17 Suppl 1: 34S–39S. doi:10.1097/00004714-199704001-00005. <nowiki>PMID 9090576</nowiki>.</ref>

=== 药代动力学 ===
米氮平的口服[[生物利用度|生物利用度]]约为50％。有85%结合到[[血浆蛋白|血浆蛋白]]。它主要在[[肝脏|肝脏]]中通过[[去甲基化|去甲基化]]和[[细胞色素P450|细胞色素P450酶]]的[[羟基化|羟基化]]代谢，其主要代谢物之一是去甲基米氮平。整体[[消除半衰期|清除半衰期]]为20~40小时。约15％由粪便、75％由尿液排出。<ref name=":18">Schatzberg, Alan F. (2009). "Chapter 21: Mirtazapine". In Schatzberg, Alan F.; Nemeroff, Charles B. ''The American Psychiatric Publishing Textbook of Psychopharmacology'' (4th ed.). Washington, D.C.: American Psychiatric Pub. ISBN 9781585623099.</ref>

== 社会文化 ==

=== 通用名 ===
Mirtazapine是该药物的[[英文|英文]]、[[法语|法文]]以及[[国际非专利药品名称|INN]]、USAN、[[美国药典|USP]]、BAN、DCF、[[欧洲商品编码|JAN]]的[[通用名药物|通用名]]。<ref name=":19">''Index Nominum 2000: International Drug Directory''. Taylor & Francis. 2000. pp. 696–. ISBN 978-3-88763-075-1.</ref><ref>I.K. Morton; Judith M. Hall (6 December 2012). ''Concise Dictionary of Pharmacological Agents: Properties and Synonyms''. Springer Science & Business Media. p. 183. ISBN 978-94-011-4439-1.</ref>它的[[西班牙语|西班牙语]]通用名是mirtazapina、[[德语|德语]]通用名是Mirtazapin、[[拉丁语|拉丁语]]通用名是mirtazapinum。<ref name=":19" />

=== 品牌名称 ===
米氮平在全球使用相当多的商品名被出售，包括：

Adco-Mirteron、Afloyan、Amirel、Arintapin Smelt、Avanza、Azapin、Beron、Bilanz、Calixta、Ciblex、Combar、Comenter、Depreram、Divaril、Esprital、Maz、Menelat、Mepirzapine、Merdaten、Meronin、Mi Er Ning、Milivin、Minelza、Minivane、Mirastad、Mirazep、Miro、Miron、Mirrador、Mirt、Mirta、Mirtabene、Mirtadepi、Mirtagamma、Mirtagen、Mirtalan、Mirtamor、Mirtamylan、Mirtan、Mirtaneo、Mirtapax、Mirtapil、Mirtapine、Mirtaron、Mirtastad、Mirtax、Mirtaz、Mirtazap、Mirtazapin、Mirtazapina、Mirtazapine、Mirtazapinum、Mirtazelon、Mirtazon、Mirtazonal、Mirtel、Mirtimash、Mirtin、Mirtine、Mirzapine、Mirzaten、Mirzest、Mitaprex、Mitaxind、Mitocent、Mitrazin、Mizapin、Motofen、Mytra、Norset、Noxibel、Pharmataz、Promyrtil、Rapizapine、Ramure、Redepra、Reflex、Remergil、Remergon、Remeron、Remirta、Rexer、Saxib、Sinmaron、Smilon、Tazepin、Tazimed、Tetrazic、Tifona、U-Mirtaron、U-zepine、Valdren、Vastat、Velorin、Yarocen、Zania、Zapex、Zestat、Zismirt、Zispin、Zuleptan、 Zulin.

=== 历史 ===
米氮平在1989年的时候由[[欧加农国际|Organon]]合成出来并被公布。首次被批准用于治疗重性抑郁障碍是在1994年的荷兰。1996年，商品名为Remeron的米氮平被引入美国。<ref name=":18" /><ref>Kaspersen, Frans M.; Van Rooij, Fons A. M.; Sperling, Eric G. M.; Wieringa, Joop H. (September 1989). "The synthesis of org 3770 labelled with 3H, 13C AND 14C". ''Journal of Labelled Compounds and Radiopharmaceuticals''. '''27''' (9): 1055–1068. doi:10.1002/jlcr.2580270911.</ref>

==引用==
{{reflist|2}}

{{抗抑郁药}}
{{OCD pharmacotherapies}}
{{Hypnotics and sedatives}}

[[Category:止吐劑|Category:止吐劑]]
[[Category:H1受体拮抗剂|Category:H1受体拮抗剂]]
[[Category:血清素拮抗剂|Category:血清素拮抗剂]]
[[Category:四环抗抑郁药|Category:四环抗抑郁药]]